"Micro TESE is associated with higher sperm retrieval rates compared with conventional testicular sperm extraction, so this approach has really become the gold standard for sperm extraction in patients with non-obstructive azoospermia," says Denise Asafu-Adjei, MD, MPH.
“Mitomycin gel, or Jelmyto, is the first agent that gives us a chance to be able to treat these low-grade upper tract cancers of the ureter and the kidney and prevent their recurrence,” says Munver.
"This non face-to-face care coordination done 'incident to' to the provider...is reimbursable through chronic care management codes," says Shirley Lee, CRNP-FNP, MPH.
“leva can help women successfully do pelvic floor muscle training and experience symptom resolution,” says Samantha Pulliam, MD.
“We really need to listen to what people care about and speak to that,” says Shirley Lee, CRNP-FNP, MPH.
Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.
A look at how PSMA PET imaging fits into the monitoring of a patient with prostate cancer.
“Any kind of complicated cancer surgery requires an experienced team from beginning to end,” says David Lee, MD.
“We had fantastic completion of the study, and we were very pleased with the results,” says Samantha Pulliam, MD.
"β3 agonists really provided a new drug class of medications for patients with overactive bladder. Previously, there were no alternatives," says Ekene Enemchukwu, MD, MPH.
“We talked about patient buy in but family caregiver buy in is just as important, especially when we're talking about cancer,” says Shirley Lee, CRNP-FNP.
“This is a unique device in that it shows motion-based biofeedback,” says Samantha Pulliam, MD.
Judd W. Moul, MD, FACS, wraps up by discussing remaining unmet needs and potential future improvements in imaging modalities for prostate cancer screening.
An expert urologic oncologist revisits a patient profile and discusses how he would have approached the patient’s prostate cancer screening process.
Judd W. Moul, MD, FACS, gives a real-world overview of how the exosome-based test is used in clinical practice.
An overview of the clinical validity and utility of a urine-based, exosomal molecular test for prostate cancer screening and risk assessment.
Judd W. Moul, MD, FACS, provides insight into the timing of biomarker testing in the prostate cancer screening process, and discusses which patients might benefit the most from testing.
Judd W. Moul, MD, FACS, introduces available blood- and urine-based biomarker tests for prostate cancer screening, and discusses how they might overcome limitations of commonly used modalities.
A focused discussion on the use of tools such as digital rectal exam, prostate biopsy, and MRI in prostate cancer diagnosis, staging, and grading.
Judd W. Moul, MD, FACS, reviews challenges of early detection of prostate cancer, and strategies to mitigate them.
A commentary on increasing trends in prostate cancer incidence and how many patients typically present with severe disease.
Judd W. Moul, MD, FACS, introduces the patient profile and discusses typical characteristics of patients undergoing prostate cancer screening in his practice.
“We…just need to apply operational efficiencies that are utilized in other industries [to] health care,” says Shirley Lee, CRNP-FNP, MPH.
“Status quo EHR [and] status quo documenting [are] not going to give us the insights that we really need about how [patients are] doing now, and what are the opportunities we have to improve their care,” says Shirley Lee, CRNP-FNP, MPH.
“Clinically speaking, it really can harm patients to have gaps in both the data and their care,” says Shirley Lee, CRNP-FNP, MPH.
A radiation oncologist explains how to discuss the interpretation of prostate cancer imaging with patients in deciding on a treatment plan.
Dr Lawrence Saperstein describes the importance of coronal images and visual analysis in making a thoughtful treatment plan for prostate cancer.
"I would say our greatest advance of the past 30 years is our clinical trials infrastructure, because we can now use our therapies with intelligence," says Anthony Zietman, MD.
Authors from the OSPREY clinical trial highlight the key take-home messages from the trial outcomes.
Key opinion leaders review the OSPREY clinical trial studying PSMA PET scans for prostate cancer imaging.
